1. An aqueous liquid pharmaceutical composition containing arbekacin and chloride ions, characterized in that the concentration of arbekacin calculated on the free base is at least 100 mg / ml and the ratio of the molar amount of chloride ions to the molar amount of arbekacin is at least 0 9: 1.2. An aqueous liquid pharmaceutical composition according to claim 1, characterized in that the molar amount of sulfate ions in the composition does not exceed 200 mol.% Of the molar amount of arbekacin. 3. An aqueous liquid pharmaceutical composition according to claim 1 or 2, characterized in that the ratio of the molar amount of chloride ions to the molar amount of arbekacin is at least 3: 1.4. An aqueous liquid pharmaceutical composition according to claim 1, characterized in that the ratio of the molar amount of chloride ions to the molar amount of arbekacin is at least 5: 1.5. An aqueous liquid pharmaceutical composition according to claim 1, characterized in that the composition practically does not contain sulfate ions. An aqueous liquid pharmaceutical composition according to claim 1, characterized in that the composition has an osmolality of at least 350 mOsmol / kg. An aqueous liquid pharmaceutical composition according to claim 1, characterized in that the composition has an osmolality from 550 to 1500 mOsmol / kg. An aqueous liquid pharmaceutical composition according to claim 1, characterized in that the composition has a pH from 3 to 7.9. An aqueous liquid pharmaceutical composition according to claim 1, characterized in that the composition has a pH from 5 to 7.10. An aqueous liquid pharmaceutical composition according to claim 1, characterized in that arbekacin is dissolved either molecularly or colloidally. Aqueous liquid pharmaceutical composition according to claim 1 for pr�1. Водная жидкая фармацевтическая композиция, содержащая арбекацин и хлорид-ионы, отличающаяся тем, что концентрация арбекацина, рассчитанная на свободное основание, составляет по меньш
